You are here

Home » Content

İNFLAMATUAR KRONİK PELVİK AĞRI SENDROMU TEDAVİSİNDE ANTİBİYOTİK + ANTİİNFLAMATUAR ve ANTİBİYOTİK + ALFA-BLOKER TEDAVİLERİNİN PLASEBO İLE KARŞILAŞTIRILMASI

COMPERISION OF ANTIBIOTiC+ANTIINFLAMATUAR and ANTIBIOTIC+ALFA BLOCKER THERAPY EFFECTIVITY COMPARISON OF INFLAMATUAR CHRONIC PELVIC PAIN SYN- DROME TREATMENTS A PLACEBO CONTROLLED STUDY

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Aim: In our study, we evaluated the effect of antibiotics together with alpha-blocker and anti-inflam-matory drugs; and we compared the effect of these treatments with placebo in patients with inflammatory chronic pelvic pain syndrome. Material and Method: Seventy-six patients with diag¬nosed NIH category 3A chronic prostatitis were included in this study. Placebo group included 19 patients (group 1), antibiotic + anti-inflammatory drug group included 29 patients (Group 2), while antibiotic + alpha-blocker group composed of 28 patients (Group 3). Before and after treatments all patients were evaluated separately according to national institutes of health-chronic prostatitis symp¬tom index (NIH- CPSI) total score and pain, voiding and life quality scores. In addition; residual urine, maximum urinary flow (Q max) and prostate specific antigen (PSA) values were evaluated. All param¬eters of the 3 groups were evaluated by t-test before and after treatments. The values of the 3 groups after treatment were compared together by Mann Whitney-U test. Result: Patients mean age was 33.31(19-51). When we compared the pre-treatment and post treatment values of the placebo group, the pain, voiding, total NIH-CPSI score; there was a significant improvement while there were no statistically difference in other parameters. In group 2, there were statistically signif¬icant change in all parameters except Qmax, residual urine. In group 3, all parameters showed sig¬nificant improvement. In comparison of the 3 groups, we found that the third group showed a more significant change than the other two groups. The patients tolerated the treatment well and there were no serious side effects. Conclusion: In our study we found that combination of antibi¬otics, alpha-blockers, and antiinflamatories are effective in treatment of category 3A chronic prosta-titis.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Çalışmamızda, inflamatuar kronik pelvik ağrı sendromu (Kronik prostatit kategori 3A) tedavisinde antibiyotikle beraber kullandığımız alfa-bloker ve antiinflamatuar tedavilerin etkinliğini araştırıp bunları plasebo ile karşılaştırdık.Gereç ve Yöntem: Kronik prostatit kategori 3A tanısı konu¬lan 76 hasta çalışmaya dahil edildi. Plasebo grubu 19 (Grup 1), antibiyotik + antiinflamatuar alan hastalar 29 (Grup 2) ve antibiyotik + alfa-bloker (Grup 3) alan hastalar 28 kişiden oluşmaktadır. Tedavi öncesi ve sonrası tüm hastalar kronik prostatit semptom indeksi (NIH-CPSI) toplam skoru, ağrı, işeme ve yaşam kalitesi skorlarına göre tek tek değerlendirildi. Bundan başka rezidüel idrar miktarı, maksi-mal idrar akım hızları(Qmax) ve prostat spesfik antijen (PSA) değerleri karşılaştırıldı. Bulgular: Hastaların yaş ortalaması 33.31 (19-51) olarak bulundu. Plasebo grubu(Grupl) tedavi öncesi ve son¬rası değerleri karşılaştırıldığında ağrı, işeme ve NIH-CPSI toplam puanında anlamlı düzelme göster-di(p<0.05), diğer parametrelerde ise istatistiksel olarak anlamlı değişme olmadı. Grup 2'de Qmax ve rezidüel idrar miktarı haricinde diğer parametrelerdeki değişim istatistiksel olarak anlamlı bulundu. Grup 3'de ise tüm parametrelerde anlamlı değişim gösterildi. Her üç grup birbirleriyle karşılaştırıldığında ise grup 3'ün daha anlamlı düzelme gösterdiği belirlendi. Tedaviler sonunda ciddi bir yan etki görülmedi ve hastalar tedavileri iyi tolere ettiler. Sonuç: Çalışmamızın sonunda kronik prostatit kategori 3A tedavisinde antibiyotik ile kombine edilen alfa-bloker ve antiinflamatuar tedavi¬lerinin etkili olduğunu ancak alfa-bloker ve antibiyotik birlikteliğinin diğer tedaviye göre daha da etk¬ili olduğu sonucuna vardık.
FULL TEXT (PDF): 
PDF icon arastirmax-inflamatuar-kronik-pelvik-agri-sendromu-tedavisinde-antibiyotik-antiinflamatuar-antibiyotik-alfa-bloker-tedavilerinin-plasebo-ile-karsilastirilmasi.pdf
  • 4
217-226
  • Turkish

REFERENCES

References: 

1. Nickel JC. Prostatitis: an historical perspective. In: Nickel JC; ed. Textbook of Prostatitis. Oxford United Kingdom ISIS Medical Media; 1999: 3-16
2. Nickel JC. Prostatitis: Evolving management strate¬gies. Urol Clin Nort Am. 1999; 26: 737-52
3. Nickel JC . Prostatitis and related conditions. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ; eds. Campbell's Urology. 8nd ed. 2003: 603-23
4. Neal DE. Acute bacterial prostatitis. In: Nickel JC; ed. Textbook of Prostatitis. Oxford United
Kingdom ISIS Medical Media 1999: 115-27
5. Nyberg LM, Krieger JN, Nickel JC. National Institues of Health classification of chronic prostati-tis. In: Nickel JC; ed. Textbook of Prostatitis.
Oxford United Kingdom ISIS Medical Media 1999: 27-9
6. Naber KG. Antibiotic Treatment of chronic bacter¬ial prostatitis. In: Nickel JC; ed. Textbook of Prostatitis. Oxford United Kingdom ISIS Medical
Media 1999: 285-92
7. Weidner W, Brunner H, Krause W. Quantitative culture of ureoplasma urealiticum in patients with chronic prostatitis or prostatotis. J Urol 1980; 124:
622-5
8. Shortliffe LM, Sellers RG, Schachter J. The charac¬terization of nonbacterial prostatitis: Search for an
aetiology. J Urol 1992; 14: 1461-6
9. Nickel, JC, Downey, J, Ardern D, Clark J, Nickel K. Failure of A Monotherapy Strategy For Difficult Chronic Prostatitis/ Chronic Pelvic Pain SyndromeJ Urology 2004; 172(2): 551-4
10. Bjerklund Johansen TE, Gruneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. 1998; 34(6): 457¬66
11. Naber KG, Madsen PO. Antibiotics. Basic con¬cepts. In: Nickel JC; ed. Textbook of Prostatitis. Oxford United Kingdom ISIS Medical Media 1999:
83-94
12. Naber KG; Antibiotic Treatment of chronic bacter¬ial prostatitis. In: Nickel JC; ed. Textbook of Prostatitis. Oxford United Kingdom ISIS Medical
Media 1999: 285-92
13. Aagard J, Knes J, Madsen PO. Prostatic tissue lev¬els of ofloxacin. Urology 1991; 38: 380-2
14. Nickel JC, Downey J, Clark J, Casey RW, Bommerville BL, Parkin J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: A randomized placebo-controlled multicen¬ter trial. Urology. 2003 Oct;62(4):614-715. Dimitrakov JD, Kaplan SA, Kroenke K, Jackson JL, Freeman MR. Management of chronic prostati-tis/chronic pelvic pain syndrome: an evidence-based approach. Urology 2006; 67(5): 881-8. Review
16. Nickel JC. Treatment of chronic prostatitis/chronic pelvic pain syndrome. Int J Antimicrob Agents. 2008 Feb;31 Suppl 1: 112-6. Epub 2007 Oct 22.
17. Morishima S, Tanaka T, Yamamoto H, Suzuki F, Akino H, Yokoyama O, et al. Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. J Urol. 2007 Jan; 177(1): 377-81.
18. Mishra VC, Browne J, Emberton M. Role of alpha-blockers in type III prostatitis: a systematic review
of the literature. J Urol. 2007 Jan; 177(1): 25-30.
Review
19. Weiss SG, Moon TD. a-Blocker Therapy. In: Nickel JC; ed. Textbook of Prostatitis. Oxford United
Kingdom ISIS Medical Media 1999: 319-327
20. Mehik A, Alas P, Nickel JC, Sarpola A, Helstörm PJ. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double blind, placebo-controlled, pilot study. Urology. 2003; 62(3): 425-9
21. Nickel JC, Downey J, Pontari MA, Shoskes DA, Zeitlin SI. A randomized placebo-controlled multi-centre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU
Int. 2004; 93(7): 991-5.
22. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yung YJ, et al; Terazosin therapy for chronic pro-statitis/chronic pelvic pain syndrome: a random¬ized, placebo-controlled trial. J Urol. 2003; 169(2):
592-6
23. Nickel, JC, Downey, J, Ardern D, et al; Failure of A Monotherapy Strategy For Difficult Chronic Prostatitis/ Chronic Pelvic Pain Syndrome. J Urol.
2004; 172(2): 551-554
24. Canale D, Scaricabarozzi I, Giorgi P, Turchi P, Ducci M, Menchini-Fabris GF; Use of a novel non-steroidal anti-inflammatory drug, nimesulide, in the treatment of abacterial prostatovesiculitis.
Andrologia. 1993; 25(3): 163-6
25. Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, et al. Rofecoxib Prostatitis Investigator Team. A randomized, placebo con¬trolled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol. 2003;
169(4): 1401-5
26. Nickel JC, Johnston B, Downey J, et al; Pentosan polysulfate therapy for chronic nonbacterial pro-statitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial.
Urology. 2000; 1, 56(3): 413-7

Thank you for copying data from http://www.arastirmax.com